LV15072A - Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai - Google Patents

Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai

Info

Publication number
LV15072A
LV15072A LVP-14-39A LV140039A LV15072A LV 15072 A LV15072 A LV 15072A LV 140039 A LV140039 A LV 140039A LV 15072 A LV15072 A LV 15072A
Authority
LV
Latvia
Prior art keywords
treatment
prevention
pharmaceutical composition
diseases associated
inos gene
Prior art date
Application number
LVP-14-39A
Other languages
English (en)
Other versions
LV15072B (lv
Inventor
Līga ZVEINIECE
Maija Dambrova
Grigorijs Veinbergs
Maksims Vorona
Ivars KALVIŅŠ
Original Assignee
Olainfarm, A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olainfarm, A/S filed Critical Olainfarm, A/S
Priority to LVP-14-39A priority Critical patent/LV15072B/lv
Priority to UAA201611303A priority patent/UA115010C2/uk
Priority to PCT/IB2015/053554 priority patent/WO2015173763A1/en
Priority to GEAP201514335A priority patent/GEP20186888B/en
Priority to EA201692221A priority patent/EA030563B1/ru
Priority to EP15739673.0A priority patent/EP3142662B1/en
Priority to US15/309,527 priority patent/US20180064687A1/en
Publication of LV15072A publication Critical patent/LV15072A/lv
Publication of LV15072B publication Critical patent/LV15072B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Izgudrojums attiecas uz (4R)-2-(4-fenil-2-oksopirolidin-1-il)acetamīda jaunu pielietojumu medicīnā, patoloģiska stāvokļa, kuram raksturīga paaugstināta iNOS gēna ekspresija, ārstēšanai.
LVP-14-39A 2014-05-14 2014-05-14 Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai LV15072B (lv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
LVP-14-39A LV15072B (lv) 2014-05-14 2014-05-14 Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai
UAA201611303A UA115010C2 (uk) 2014-05-14 2015-05-14 Застосування фармацевтичної композиції для профілактики та лікування хвороб, обумовлених підвищеним рівнем індуцибельної синтази оксиду азоту
PCT/IB2015/053554 WO2015173763A1 (en) 2014-05-14 2015-05-14 Pharmaceutical composition for the prevention and treatment of diseases associated with elevated inducible nitric oxide synthase
GEAP201514335A GEP20186888B (en) 2014-05-14 2015-05-14 Pharmaceutical composition for the prevention and treatment of diseases associated with elevated inducible nitric oxide synthase
EA201692221A EA030563B1 (ru) 2014-05-14 2015-05-14 Фармацевтическая композиция для профилактики и лечения периферической невропатии
EP15739673.0A EP3142662B1 (en) 2014-05-14 2015-05-14 Pharmaceutical composition for the prevention and treatment of diseases associated with elevated inducible nitric oxide synthase
US15/309,527 US20180064687A1 (en) 2014-05-14 2015-05-14 Pharmaceutical composition for the prevention and treatment of diseases associated with elevated inducible nitric oxide synthase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-14-39A LV15072B (lv) 2014-05-14 2014-05-14 Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai

Publications (2)

Publication Number Publication Date
LV15072A true LV15072A (lv) 2015-11-20
LV15072B LV15072B (lv) 2016-09-20

Family

ID=53716523

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-14-39A LV15072B (lv) 2014-05-14 2014-05-14 Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai

Country Status (7)

Country Link
US (1) US20180064687A1 (lv)
EP (1) EP3142662B1 (lv)
EA (1) EA030563B1 (lv)
GE (1) GEP20186888B (lv)
LV (1) LV15072B (lv)
UA (1) UA115010C2 (lv)
WO (1) WO2015173763A1 (lv)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV13630B (en) 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
TW201408294A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除

Also Published As

Publication number Publication date
EP3142662B1 (en) 2020-07-08
US20180064687A1 (en) 2018-03-08
GEP20186888B (en) 2018-08-27
EA030563B1 (ru) 2018-08-31
WO2015173763A1 (en) 2015-11-19
UA115010C2 (uk) 2017-08-28
EA201692221A1 (ru) 2017-05-31
LV15072B (lv) 2016-09-20
EP3142662A1 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
TW201613901A (en) New compounds
EP3212233A4 (en) Combination therapy for treatment of disease
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
HRP20180641T1 (hr) Pirolidinski gpr40 modulatori za liječenje bolesti kao što je dijabetes
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
IL272601A (en) Pharmaceutical preparations for the treatment of ophthalmic conditions
EP3328864A4 (en) COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
IL248670A0 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
HK1259373A1 (zh) 用於治療糖尿病的藥物製劑
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
EP3310396A4 (en) THERAPEUTIC HYDROGELS BASED ON NANOFIBRES FOR THE LOCAL TREATMENT OF BRAIN DISEASES
EP3310310A4 (en) DEVICE FOR TREATING MENIÈRE DISEASE
IL259381B (en) Miravegron for the treatment of retinal diseases
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
LV15072A (lv) Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai
GB201720101D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
AU2016905281A0 (en) Pharmaceutical composition for treatment of an eye disease or condition
AU2016904360A0 (en) Pharmaceutical composition for treatment of an eye disease or condition
EP3247396A4 (en) Methods and compositions for the treatment of diseases and disorders
EP3129054A4 (en) Methods and compositions for the treatment of ocular diseases and disorders